Nouvelles

Nouvelles

15 février 2012	REPLICor to disclose interim REP 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012) (anglais seulement)

25 novembre 2011	REPLICor to disclose new mechanism of action data and interim REP 9AC and REP 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 2011 HEPDART meeting. (anglais seulement)

27 octobre 2011	REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD 2011) (anglais seulement)

30 mars 2011	REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 46th meeting of the European Association for the Study of the Liver (EASL 2011) (anglais seulement)

17 février 2011	REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011) (anglais seulement)

28 octobre 2010	REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 61st annual meeting of the AASLD in Boston, U.S.A. (anglais seulement)

18 mars 2010	REPLICor to present interim REP 9AC clinical efficacy data at the 20th annual meeting of the APASL in Beijing, China (anglais seulement)

8 décembre 2009	Dr. Allison Jilbert presents preclinical efficacy data for REP 9AC in DHBV infected Pekin ducks (anglais seulement)

2 décembre 2009	REPLICor publishes data on the activity and safety of amphipathic DNA polymers (APs) in cytomegalovirus infection (anglais seulement)

23 avril 2009	Publication of REPLICor’s first in class HCV entry inhibitor based on its amphipathic DNA polymer technology (anglais seulement)

16 avril 2009	REPLICor publishes data on mechanism of action and pre-clinical efficacy of amphipathic DNA polymers (APs) in HCV infection (anglais seulement)

31 mars 2009	REPLICor to present preclinical data showing a curative response to hepatitis B infection with its drug at the 1^st Annual Girindus Leaders in Oligonucletides Meeting (anglais seulement)

Mars 2009	REPLICor initiates dosing of human patients with its drug (anglais seulement)

Février, 2009	REPLICor receives IRB approval to conduct a phase I / II trial to test the safety and efficacy of its drug in patients with chronic hepatitis B and hepatitis C (anglais seulement)

13 avril 2008	REPLICor to Present at the 21st International Conference on Antiviral Research (anglais seulement)
10 janvier 2008	REPLICor : Une Entreprise Audacieuse

6 décembre 2007

REPLICor’s Data on REP 9C / REP 9AC Presented at the HEPDART Meeting (anglais seulement)

4 décembre 2007

REPLICor Recognized as a Top 10 Life Sciences Companies in Canada (anglais seulement)

30 novembre 2007

REPLICor Receives Notice of Allowance for Key Patent Application (anglais seulement)

16 septembre 2007

REPLICor to Present at the RSC Virus Molecular Interactions Conference (anglais seulement)

10 septembre 2007

REPLICor Collaborators to Present at the HBV Meeting (anglais seulement)

8 septembre 2007

REPLICor to Present at the 14^th Symposium of Hepatitis C and Related Viruses (anglais seulement)

23 avril 2007

REPLICor to Present at 20th International Conference on Antiviral Research (anglais seulement)

28 février 2007

REPLICor to Present at the 3rd Annual Viral Hepatitis in Drug Discovery & Development World Summit (anglais seulement)

24 octobre 2006

REPLICor to disclose results of its first-in-class drugs against hepatitis C (anglais seulement)

19 septembre 2006

REPLICor's Drug Activity in the Metabolic Syndrome (anglais seulement)

21 juin 2006

REPLICor Presenting at Metabolic Diseases Summit (anglais seulement)

5 mai 2006

REPLICor to present at the American Society for Microbiology General Meeting 2006 (anglais seulement)

5 mai 2006

REPLICor to present at the 19th International Conference on Antiviral Research (anglais seulement)

5 mai 2006

Oligos Enable New Classes of Therapeutics (anglais seulement)

28 avril 2006

REPLICor to present at TIDES 2006 (anglais seulement)

22 avril 2006

REPLICor, NIAID identify potential anti-prion therapeutic (anglais seulement)

5 avril 2006

Le médicament antiviral de REPLICor est efficace contre la grippe aviaire H5N1

1er novembre 2005	Le médicament antiviral de REPLICor promet une activité efficace contre la grippe aviaire H5N1
11 avril 2005	REPLICor Describes its Corporate Strategies in the Biomed Business Journal (anglais seulement)
30 mars 2005	REPLICor to Disclose Unique Broad Spectrum Antiviral Drug (anglais seulement)

10 novembre 2004	Girindus to Produce Antiviral Treatment for Canada's Replicor (anglais seulement)

8 novembre 2004	REPLICor Named One of Canada’s Top Ten Life Science Companies (anglais seulement)